The Nuclear Oncology Council was formed in 2003 by the merger of the former SNMMI Clinical Trials and Therapy Council. The NOC membership is comprised of all categories of SNMMI members (physicians, scientists, technologists, radiopharmacists, industry representatives, residents, students, and educators). The NOC's mission to be the recognized world leader in providing knowledge that advances and promotes the use of radiotherapuetic agents, devices and radiopharmaceuticals in molecular imaging, and which vigorously supports the expansion of clinical trials for such agents, devices, and/or radiopharmaceuticals.
The initial goals of the NOC include:
To foster and encourage the scientific interchange of ideas among nuclear medicine professionals in imaging that utilizes radiopharmaceuticals, radiotherapuetic agents and related devices and who have an interest in expanding the use of radiopharmaceuticals for therapeutic purposes
To promote both basic and clinical research in the therapeutic uses of radiotherapuetic agents, devices, or radiopharmaceuticals
To serve the SNMMI and the global nuclear medicine community as the source of all research activities and clinical applications of radiotherapuetic agents and devices.
Neeta Pandit-Taskar, MD
President, Nuclear Oncology Council
As the SNMMI continues it emphasis and efforts in expanding the scope and practice of molecular imaging modalities, the Nuclear oncology will continue to focus its attention on the use and optimization of tracers for targeted imaging and therapy. By strategic planning and efforts of the governing members we plan to further efforts in improving the knowledge and utilization of the current modalities and work with the SNMMI leadership in expanding the scope to newer modalities.
The Nuclear Oncology Council was formed in 2003 by the merger of the former SNM Clinical Trials and Therapy Council. The NOC's mission is to be recognized as world leader in providing knowledge that advances and promotes the use of radiotherapuetic agents, devices and radiopharmaceuticals in molecular imaging, and which vigorously supports the expansion of clinical trials for such agents, devices, and/or radiopharmaceuticals. The NOC vision is to provide its members and Nuclear medicine community resources to gain knowledge, improve practice and patient care by optimizing the utilization of targeted imaging and therapy.
The goals of the NOC include:
The membership is comprised of physicians, scientists, technologists, radiopharmacists, industry representatives and trainees. NOC provides a forum for members to contribute to the development of the field of nuclear oncology through regular communications among members as well as collaboration and interaction during educational and administrative sessions at national meetings. The field of nuclear oncology sees constant changes and advances with the introduction of new tracers for diagnostic applications and novel agents for therapy.
NOC aims to create a stronger voice to achieve greater recognition of the targeted radiopharmaceutical therapies in the clinical community including oncologists to greater utilization and expand the applications in general practice. Our goal is to enhance knowledge of the general physicians and oncologist to the advantages of targeted radiopharmaceutal imaging and therapy and understand hurdles that restrain or limit the use of targeted radiopharmaceutical agents. Training of new scientists and physicians in the field of nuclear oncology is critical to the growth of the field and NOC will take new initiatives to involve and train young professionals through collaboration and increased interactions.
In the next two years, NOC will work on improvising and emphasizing the optimal use of therapeutic agents and growth of theranostics. A thyroid therapy task force will help understand the clinical and practice related issues that govern the use of RAI for imaging and therapy, impact of the guidelines and suggestions to expand knowledge and utilization of RAI imaging and therapy in management of thyroid cancer. Task force on neuroendocrine therapy and imaging will focus on 131 I MIBG therapy and guidelines and Ga 68 labeled somatostatin analog and provide educational resources for those interested in clinical utilization of these modalities.
Theranostics is an extremely interesting and important development in the field. NOC efforts will aim to expand knowledge and resource for the imaging community and those interested in clinical translation of the technology. Educational sessions will be planned at the meetings to enable those interested in gaining knowledge of this technology. NOC will collaborate and partner with other councils or individuals with similar interest to make this successful.
This year, NOC is partnering with the YIA and CMIIT in CE sessions to address the use of radiopharmaceuticals and novel therapeutic agents like Xofigo (Ra-223 chloride). A CE session on theranostics will address novel tracers and techniques. The sessions will provide a review of novel and emerging techniques and the issues related to the technique including potential clinical applications in oncologic imaging. Previously, NOC established outreach contacts with the American Society for Therapeutic Radiology and Oncology (ASTRO) and with the American Society of Clinical Oncology (ASCO). We aim to continue to do so in following years.
Through continued efforts, the council aims to be an effective source and leader in the enhancement of the field of targeted radiopharmaceuticals in imaging and therapy. The council is committed to the community and the members and involvement of members is vital for our growth. NOC seeks and encourages involvement of all its members to contribute ideas and suggestions that will help us meet our goals and better serve the community. The council invites and welcomes all to contribute to the development of the content of our educational activities, and strengthen the organization by identifying and help resolve issues that currently limit the field.
I encourage you to join the council. Please feel free to contact me or any of the members of the NOC board of directors with suggestions and comments.
Nuclear Oncology Council Young Investigator Awards Symposium
SNMMI-sponsored symposium and competition, in association with the SNMMI Nuclear Oncology Council, for the best scientific abstracts on neurosciences nuclear medicine. Learn more about the NOC Young Investigator Awards.
The Society recognizes the need for sub-specialty interests/expertise within the field of nuclear medicine and moleuclar imaging. Councils provide the expertise, professional networking and educational programs for nuclear medicine professionals in respective areas and serve as a resource for development and implementatin of Society policies.
Council membership is voluntary. Councils adhere to Society Bylaws and policies, while operating under its own Operating Procedures, as approved by the House of Delegates, and its own business plan and budget, as approved by the SNMMI Board of Directors.
This section provides the following council specific information.
NOC Board of Directors
NOC Operating Procedures
NOC Business Plan
NOC Committees and Committee Members
NOC Council Reports to the House of Delegates
NOC Past Presidents
How to Become a Member
Membership in the Nuclear Oncology Council is limited to members of the SNMMI. Membership can be attained by indicating the desire to join during the annual renewal of the SNMMI membership or by filing an application with the Secretary of the council.
Payment of Dues
Membership in the NOC requires payment of dues in the amount of $20/year. Dues are paid to SNMMI and will be due on October 1st of each year.
Benefits of Membership:
Membership makes you a part of a professional group within the SNMMI that:
Provides continuing education for professionals in the various areas relating to Nuclear Oncology through sponsored symposia and continuing education courses. Each year the NOC puts on a Categorical Seminar or symposia, and Continuing Education Courses on topics of interest to professionals using radiopharmaceuticals.
Provides a forum and a mechanism for discussion and dissemination of information relating to radiopharmaceuticals, radiotherapuetic agents and related devices. The NOC members receive periodic Newsletters and electronic mailings containing information on professional activities, government issues, and a host of other related topics. Members will soon have access to NOC Web pages, which will contain timely and archived information relating to a variety of topics.
Provides expertise in the radiopharmaceuticals, radiotherapuetic agents and related devices to SNMMI leadership and to groups outside of SNMMI seeking such expertise. The NOC has representation in a number of governance groups within SNMMI, including the Committee on Councils and the House of Delegates.
Learn more about the specific benefits the NOC council has to offer.
Visit BOD Community
Council membership is voluntary. Society members are eligible for council membership, and can belong to as many councils as they wish. The Nuclear Oncology Council dues are $20.00. Join this council now.
Learn more about the Nuclear Oncology Council member benefits.
SNMMI Nuclear Oncology Council
1850 Samuel Morse Drive
Reston, VA 20190